论文部分内容阅读
目的 评价SRCA法与MTT比色法测定肿瘤对药物的敏感性试验中的差异 ,探讨引起这种差异的可能原因 ,为临床应用提供理论依据。方法 取新鲜直肠癌标本进行SRCA法及MTT法 ,分为 5 -FU、MMC、MTX组。SRCA法术后第 1、3、5d裸鼠各组分别皮下注射 5 -FU、MMC、MTX ,术后第 6d测定移植肿瘤消退率 ;MTT法各组以相应的药物的血浆峰浓度的 1/10作为试验浓度 ,第 4d测定肿瘤细胞的抑制率。结果 60组肿瘤对化疗药物敏感性结果中 ,符合 2 0对 ,不符合 40对 ,两方法间药物敏感性阳性和阴性结果符合率为 33 3% ,差异有统计学意义。结论 MTT法与SRCA法肿瘤药物敏感试验结果之间存在差异
OBJECTIVE: To evaluate the differences between the SRCA assay and the MTT assay in determining the sensitivity of tumor to drugs, and to explore the possible causes of such differences and to provide a theoretical basis for clinical application. Methods Fresh colorectal cancer specimens were taken for SRCA assay and MTT assay and divided into 5-FU, MMC and MTX groups. The mice in each group were injected with 5-FU, MMC and MTX subcutaneously on the 1st, 3rd and 5th day after SRCA, and the tumor regression rate was measured on the 6th day after the operation. The peak plasma concentration of 1 / 10 as a test concentration, and the inhibition rate of tumor cells was measured on the 4th day. Results Among the 60 groups, the sensitivity to chemotherapeutic drugs was 20 pairs, which did not fit 40 pairs. The coincidence rate of positive and negative drug sensitivity between the two methods was 33.3%, the difference was statistically significant. Conclusion There are differences between MTT assay and SRCA oncology drug sensitivity test results